Jump to content

Data from a Phase II trial of ARN-509 (apalutamide)

Paul Edwards

Recommended Posts

"It is clear from these data that apalutamide has activity in the treatment of men with nmCRPC. This is not a surprise. However, the degree of promise for apalutamide based on these data (compared to other drugs already available on the market) is much harder to evaluate. Would treatment of this set of patients with either enzalutamide or abiraterone acetate have shown similar outcomes? We really don’t know."


Click on this link to read an article in the New Prostate Cancer Infolink about a recent Phase II trial.



Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...